Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.
| Revenue (Most Recent Fiscal Year) | $23.68M |
| Net Income (Most Recent Fiscal Year) | $-318.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 17.92 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.89 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -428.48% |
| Net Margin (Trailing 12 Months) | -428.48% |
| Return on Equity (Trailing 12 Months) | -130.47% |
| Return on Assets (Trailing 12 Months) | -56.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.55 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.06 |
| Inventory Turnover (Trailing 12 Months) | 0.53 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.83 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.83 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.72 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.89 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 86.14M |
| Free Float | 82.61M |
| Market Capitalization | $1.40B |
| Average Volume (Last 20 Days) | 3.02M |
| Beta (Past 60 Months) | 0.74 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.10% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |